| Literature DB >> 32838199 |
Amir H Davarpanah1,2, Reyhaneh Asgari1, Yashar Moharamzad1, Arash Mahdavi1, Alireza Abrishami1, Sayyedmojtaba Nekooghadam1, Ali Sabri3, Ehsan Zarei1, Mehdi Khazaei1, Morteza Sanei Taheri1,4.
Abstract
We investigated significant predictors of poor in-hospital outcomes for patients admitted with viral pneumonia during the COVID-19 outbreak in Tehran, Iran. Between February 22 and March 22, 2020, patients who were admitted to three university hospitals during the COVID-19 outbreak in Tehran, Iran were included. Demographic, clinical, laboratory, and chest CT scan findings were gathered. Two radiologists evaluated the distribution and CT features of the lesions and also scored the extent of lung involvement as the sum of three zones in each lung. Of 228 included patients, 45 patients (19.7%) required ICU admission and 34 patients (14.9%) died. According to regression analysis, older age (OR = 1.06; P < 0.001), blood oxygen saturation (SpO2) < 88% (OR = 2.88; P = 0.03), and higher chest CT total score (OR = 1.10; P = 0.03) were significant predictors for in-hospital death. The same three variables were also recognized as significant predictors for invasive respiratory support: SpO2 < 88% (OR = 3.97, P = 0.002), older age (OR = 1.05, P < 0.001), and higher CT total score (OR = 1.13, P = 0.008). Potential predictors of invasive respiratory support and in-hospital death in patients with viral pneumonia were older age, SpO2 < 88%, and higher chest CT score. © Springer Nature Switzerland AG 2020.Entities:
Keywords: COVID-19; Patient outcome assessment; Pneumonia; Prognosis; Tomography, X-ray computed
Year: 2020 PMID: 32838199 PMCID: PMC7434489 DOI: 10.1007/s42399-020-00445-3
Source DB: PubMed Journal: SN Compr Clin Med ISSN: 2523-8973
Fig. 1Flowchart of the patients with viral pneumonia during the COVID-19 outbreak included in the study
Fig. 2A 30-year-old female presented with fever and cough. Her initial blood oxygen saturation was 96% on room air. Axial (A) and sagittal (B) reconstructions of low dose spiral CT scan of the chest revealed patchy ground glass opacities most prominently in bilateral lower lobes with total CT score of 5. The patient was admitted to the ward and discharged after six days with good general conditions
Fig. 3A 65-year-old male presented with fever and dyspnea. His blood oxygen saturation was 88% on room air with respiratory rate of 40 per minute. Scout view demonstrated severe bilateral air-space consolidation (A). CT scan also revealed widespread patchy air-space consolidation in bilateral lungs, more prominent in the upper lung regions, with calculated total CT score of 19 (B and C). Subsequently, the patient was admitted to the intensive care unit
Clinical presentations, vital signs, and comorbidities among 228 patients with viral pneumonia admitted to the studied hospitals during the COVID-19 outbreak in Tehran, Iran
| Variables | Total ( | ICU admission ( | ICU non-admission ( | Non-survivors ( | Survivors ( | ||||
|---|---|---|---|---|---|---|---|---|---|
| Presenting symptom | Coughing | 158 (69.3%) | 23 (14.6%) | 135 (85.4%) | 17 (10.8%) | 141 (89.2%) | |||
| Dyspnea | 140 (61.4%) | 29 (20.7%) | 111 (79.3%) | 0.64 | 21 (15%) | 119 (85%) | 0.96 | ||
| Myalgia | 75 (32.9%) | 11 (14.7%) | 64 (85.3%) | 0.17 | 7 (9.3%) | 68 (90.7%) | 0.11* | ||
| GI symptoms | 49 (21.5%) | 11 (22.4%) | 38 (77.6%) | 0.59 | 10 (20.4%) | 39 (79.8%) | 0.22 | ||
| Vital signs | Fever | 28 (13.3%) | 9 (32.1%) | 19 (67.9%) | 0.08 | 5 (17.9%) | 23 (82.1%) | 0.72 | |
| Tachycardia | 49 (22.2%) | 17 (34.7%) | 32 (65.3%) | 13 (26.5%) | 36 (73.5%) | ||||
| Tachypnea | 50 (23.4%) | 35 (70%) | 15 (30%) | 0.06 | 11 (22%) | 39 (78%) | 0.17 | ||
| Systolic BP, mmHg | 117.5 (± 13.2) | 117.7 (± 16.6) | 117.5 (± 12.4) | 0.93 | 117.6 (± 17.6) | 117.5 (± 12.4) | 0.96 | ||
| Diastolic BP, mmHg | 75.6 (± 8.6) | 76 (± 11.9) | 75.5 (± 7.7) | 0.76 | 76.4 (± 12.6) | 75.4 (± 7.8) | 0.59 | ||
| Blood O2 saturation | > 93% | 63 (29%) | 6 (9.5%) | 57 (90.5%) | 4 (6.4%) | 59 (93.6%) | |||
| 88–93% | 96 (44.2%) | 12 (12.5%) | 84 (87.5%) | 10 (10.4%) | 86 (89.6%) | ||||
| < 88% | 58 (26.8%) | 26 (44.8%) | 32 (55.2%) | 19 (32.8%) | 39 (67.2%) | ||||
| Comorbidity | Ischemic heart disease | 42 (18.4%) | 11 (26.2%) | 31 (73.8%) | 0.24 | 10 (23.8%) | 32 (76.2%) | 0.07 | |
| Diabetes mellitus | 46 (20.2%) | 10 (21.7%) | 36 (78.3%) | 0.70 | 6 (13%) | 40 (87%) | 0.81* | ||
| Hypertension | 70 (30.7%) | 14 (20%) | 56 (80%) | 0.94 | 13 (18.6%) | 57 (81.4%) | 0.30 | ||
| Chronic lung disease | 18 (7.9%) | 4 (22.2%) | 14 (77.8%) | 0.76* | 3 (16.7%) | 15 (83.3%) | 0.73* | ||
| Chronic renal failure | 14 (6.1%) | 6 (42.9%) | 8 (57.1%) | 5 (35.7%) | 9 (64.3%) | ||||
| Renal transplant recipient | 3 (1.3%) | 2 (66.7%) | 1 (33.3%) | 0.10* | 0 | 3 (100%) | 1.0* | ||
There were missing data for fever, tachypnea, and blood oxygen saturation; continuous data are presented as mean (±standard deviation)
GI gastrointestinal, BP blood pressure
*P values were derived using the non-parametric Kruskal-Wallis test
Laboratory findings on admission among 228 patients with viral pneumonia admitted to the studied hospitals during the COVID-19 outbreak in Tehran, Iran
| Variables | Total ( | ICU admission ( | ICU non-admission ( | Non-survivors ( | Survivors ( | |||
|---|---|---|---|---|---|---|---|---|
| Leukocytosis | 21 (9.5%) | 13 (61.9%) | 8 (38.1%) | 11 (52.4%) | 10 (47.6%) | |||
| Lymphopenia | 155 (70.1%) | 34 (21.9%) | 121 (78.1%) | 0.24 | 27 (17.4%) | 128 (82.6%) | 0.11 | |
| Platelet count, ×103/mL | > 150 | 153 (68.9%) | 30 (19.6%) | 123 (80.4%) | 0.96 | 22 (14.4%) | 131 (85.6%) | 0.90* |
| 50–100 | 53 (23.9%) | 11 (20.7%) | 42 (79.3%) | 9 (17%) | 44 (83%) | |||
| < 50 | 16 (7.2%) | 3 (18.7%) | 13 (81.3%) | 2 (12.5%) | 14 (87.5%) | |||
| Creatinine, mg/dL | < 1.2 | 101 (47%) | 13 (12.9%) | 88 (87.1%) | 9 (8.9%) | 92 (91.1%) | ||
| 1.9–5.9 | 85 (39.5%) | 11 (13%) | 74 (87%) | 10 (11.8%) | 75 (88.2%) | |||
| > 5.9 | 26 (12.1%) | 18 (69.2%) | 8 (30.8%) | 13 (50%) | 13 (50%) | |||
| 4 | 3 (1.4%) | 1 (33.3%) | 2 (66.7%) | 1 (33.3%) | 2 (66.7%) | |||
| BUN, mg/dL | 29.01 (± 30.58) | 49.3(±39.9) | 24.1 (± 25.7) | 50.05 (40.9) | 25.4 (27) | |||
| Elevated ALT | 19 (20.9%) | 5 (26.3%) | 14 (73.7%) | 0.33 | 2 (10.5%) | 17 (89.5%) | 0.72* | |
| Elevated AST | 36 (38.7%) | 12 (33.3%) | 24 (66.7%) | 9 (25%) | 27 (75%) | |||
| Elevated AlkP | 69 (75%) | 17 (24.6%) | 52 (75.4%) | 13 (18.8%) | 56 (81.2%) | 0.17* | ||
| Abnormal pH | 30 (16.3%) | 14 (46.7%) | 16 (53.3%) | 11 (36.7%) | 19 (63.3%) | |||
| PO2, mmHga | 32.6 (± 17.6) | 37.5 (± 23.6) | 31.2 (± 15.2) | 0.15* | 38.9 (± 26) | 31.3 (±15) | 0.15* | |
| Elevated blood CO2 | 62 (33.7%) | 13 (21%) | 49 (79%) | 0.76 | 9 (14.5%) | 53 (85.5%) | 0.46 | |
| PCO2, mmHg | 44.6 (± 35.5) | 40.9 (± 11.4) | 45.7 (± 39.8) | 0.16* | 40.8 (± 11.4) | 45.4 (±38.7) | 0.27 | |
| HCO3−, mEq/L | 23.7 (± 4.5) | 21.4 (± 5.4) | 24.3 (± 4) | 21.1 (5.2) | 24.2 (4.2) | |||
| ESR, mm/h | 38.2 (± 26.5) | 47.3 (35.7) | 36.1 (23.7) | 0.32* | 40 (± 29.1) | 37.9 (± 26.2) | 0.75 | |
| CRP, mg/L | 37 (± 31.6) | 50.4 (± 46.9) | 34 (± 26.4) | 0.16* | 58.5 (± 48.3) | 33.7 (± 26.7) | ||
| LDH, U/L | 543.9 (± 273.9) | 743 (±400.6) | 488.3 (±195.8) | 807.6 (± 409.6) | 487.4 (± 196) | |||
| Sodium, mg/dL | 136.4 (± 4.4) | 137.4 (± 7.4) | 136.2 (± 3.3) | 0.16 | 137.7 (± 8) | 136.2 (± 3.4) | 0.11* | |
| Potassium, mg/dL | 4 (± 0.48) | 4.3 (± 0.7) | 3.9 (± 0.4) | 4.2 (± 0.8) | 4 (± 0.4) | 0.16* | ||
Continuous data are presented as mean (±standard deviation)
ALT alanine aminotransferase, AST aspartate aminotransferase, ALKP alkaline phosphatase, ESR erythrocyte sedimentation rate, CRP C-reactive protein, LDH lactate dehydrogenase
*P values were derived using the non-parametric Kruskal-Wallis test
ªThe values were assayed using sample of venous blood
Chest CT scan findings among 228 patients with viral pneumonia admitted to the studied hospitals during the COVID-19 outbreak in Tehran, Iran
| Total ( | ICU admission ( | ICU non-admission ( | Non-survivors ( | Survivors ( | ||||
|---|---|---|---|---|---|---|---|---|
| Ground glass opacity | 153 (67.1%) | 32 (15%) | 130 (85%) | 22 (14.4%) | 131 (85.6%) | 0.74 | ||
| Consolidation | 43 (18.9%) | 14 (32.6%) | 29 (67.4%) | 8 (18.6%) | 35 (81.4%) | 0.45 | ||
| Reticular opacities | 20 (8.8%) | 5 (25%) | 15 (75%) | 0.55* | 2 (10%) | 18 (90%) | 0.74* | |
| Mixed opacities | 13 (5.7%) | 3 (23.1%) | 10 (76.9%) | 0.72* | 2 (15.4%) | 11 (84.6%) | 1.0* | |
| Round opacities | 39 (17.1%) | 5 (12.8%) | 34 (87.2%) | 0.27* | 3 (7.7%) | 36 (92.3%) | 0.21* | |
| Linear opacities | 76 (33.3%) | 15 (19.7%) | 61 (82.3%) | 1.0 | 9 (11.8%) | 67 (88.2%) | 0.35 | |
| Pleural effusion | 24 (10.5%) | 12 (50%) | 12 (50%) | 9 (37.5%) | 15 (62.5%) | |||
| Pericardial effusion | 19 (8.3%) | 5 (26.3%) | 14 (73.7%) | 0.54* | 3 (15.8%) | 16 (84.2%) | 1.0* | |
| Emphysema | 6 (2.6%) | 3 (50%) | 3 (50%) | 0.09* | 2 (33.3%) | 4 (66.7%) | 0.22* | |
| Fibrosis | 5 (2.2%) | 1 (20%) | 4 (80%) | 1.0* | 1 (20%) | 4 (80%) | 0.55* | |
| Bronchiectasis | 5 (2.2%) | 1 (20%) | 4 (80%) | 1.0* | 1 (20%) | 4 (80%) | 0.55* | |
| Bronchial wall thickening | 62 (27.2%) | 19 (30.6%) | 43 (69.4%) | 14 (22.6%) | 48 (77.4%) | |||
| Crazy paving | 17 (7.5%) | 3 (17.6%) | 14 (82.4%) | 1.0* | 0 | 17 (100%) | 0.08* | |
| Reverse halo sign | 15 (6.6%) | 0 | 15 (100%) | 0 | 15 (100%) | 0.13* | ||
| Lymphadenopathy | 5 (2.2%) | 1 (20%) | 4 (80%) | 1.0 | 1 (20%) | 4 (80%) | 0.55* | |
| Axial distribution | Both | 41 (18%) | 11 (26.8%) | 30 (73.2%) | 9 (22%) | 32 (78%) | 0.12* | |
| Central | 29 (12.7%) | 11 (37.9%) | 18 (62.1%) | 7 (24.1%) | 22 (78.9%) | |||
| Peripheral | 156 (68.4%) | 23 (14.7%) | 133 (85.3%) | 18 (11.5%) | 138 (88.5%) | |||
| None | 2 (0.9%) | 0 | 2 (100%) | 0 | 2 (100%) | |||
Craniocaudal distribution | Diffuse | 68 (29.8%) | 13 (19.1%) | 55 (80.9%) | 0.71* | 14 (20.6%) | 54 (79.4%) | 0.22* |
| Lower | 122 (53.5%) | 25 (20.5%) | 97 (79.5%) | 15 (12.3%) | 107 (87.7%) | |||
| Mid | 20 (8.8%) | 3 (15%) | 17 (85%) | 3 (15%) | 17 (85%) | |||
| None | 1 (0.4%) | 0 | 1 (100%) | 0 | 1 (100%) | |||
| Upper | 17 (7.5%) | 4 (23.5%) | 13 (76.5%) | 2 (11.8%) | 15 (88.2%) | |||
*P values were derived using the non-parametric Kruskal-Wallis test
Results of multivariable logistic regression model to determine significant predictors for ICU admission and in-hospital death among 228 patients with viral pneumonia admitted to the studied hospitals during the COVID-19 outbreak in Tehran, Iran. SE= standard error; OR= odds ratio; CI= confidence interval
| Outcome | Variables | Beta (estimate) | SE | Adjusted OR | 95% CI | |
|---|---|---|---|---|---|---|
| In-hospital death | Age (per 1 year increase) | 0.06 | 0.01 | < 0.001 | 1.06 | 1.03 to 1.10 |
| Total CT score (per 1 score increase) | 0.10 | 0.05 | 0.03 | 1.10 | 1.00 to 1.22 | |
| Blood oxygen saturation < 88% | − 0.52 | 0.24 | 0.03 | 2.88 | 1.09 to 7.62 | |
| Intercept | − 6.77 | 1.41 | < 0.001 | |||
| ICU admission | Age (per 1 year increase) | 0.05 | 0.01 | < 0.001 | 1.05 | 1.02 to 1.09 |
| Total CT score (per 1 score increase) | 0.12 | 0.04 | 0.008 | 1.13 | 1.02 to 1.24 | |
| Blood oxygen saturation < 88% | − 0.68 | 0.22 | 0.002 | 3.97 | 1.61 to 9.74 | |
| Intercept | − 5.83 | 1.26 | < 0.001 | |||